| abstract |
The present invention relates to GPR6 modulator compounds of Formula I where R1 is C3-C8 cycloalkyl, C3-C6 heterocyclyl and C1-C10 heteroaryl each optionally substituted; X1 is N and X2 is CH or X1 is CH and X2 is N or X1 is N and X2 is N; Z is C1-C6 alkylene, C1-C6 haloalkylenes, among others; q, s and p are 0, 1 or 2; R2 is -OR5 or -NR6R7; R3 is C1-C6 alkyl, C3-C8 cycloalkyl, and trifluoromethyl; R4 is C1-C6 alkyl, hydroxy or halo; r is 0 or 1; R5 is C1-C6 alkyl and C3-C8 cycloalkyl; R6 is hydrogen and C1-C6 alkyl; R7 is C1-C6 alkyl, C3-C8 cycloalkyl, among others; X3 is CH and CR4 and X4 is NR8 or vice versa and R8 is C1-C6 alkyl, C1-C6 haloalkyl, among others. Preferred compounds are: cyclopropyl-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H) -yl)methanone; 1-(2-(4-(2,4-difluorophenoxy)piperidin-1-yl)-3-(isopropylamino)-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl)- 2-methoxyethane-1-one; among others. Said compounds are derivatives of tetrahydropyridopyrazines being useful in the treatment of conditions associated with GPR6 |